Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
NCT ID: NCT03801135
Last Updated: 2019-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2018-10-03
2019-09-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
NCT06571552
Pre- Vs Postoperative Thromboprophylaxis for Liver Resection
NCT04731558
Ascending Doses of Autologous FDP vs FFP
NCT02930226
Hemostasis Profile in Patients With Severe Subarachnoid Hemorrhage
NCT03745456
Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas
NCT05491356
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Electrolyte&Albumin Group
One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
No interventions assigned to this group
Fibrinogen Treatment Group
One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
Fibrinogen concentrate
Haemocomplettan will be infused after plasma exchange procedure
FFP Treatment Group
One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
Fresh Frozen Plasma
Fresh frozen plasma will be part of replacement fluid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fibrinogen concentrate
Haemocomplettan will be infused after plasma exchange procedure
Fresh Frozen Plasma
Fresh frozen plasma will be part of replacement fluid
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* coagulation disorders
* Hypertriglyceridemia-induced acute pancreatitis
* hepatic disorders
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matej Zrimsek
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Centre Ljubljana
Ljubljana, Gorenjska, Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zrimsek M, Gubensek J, Marn Pernat A. A Pilot Study on the Replacement of Fibrinogen with Fibrinogen Concentrates During Therapeutic Plasma Exchange with Mild to Moderate Bleeding Risk-A Comparison with Fresh Frozen Plasma and Albumin Replacement. J Clin Med. 2024 Dec 16;13(24):7662. doi: 10.3390/jcm13247662.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPFhemostaza
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.